Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

ICA-1: A novel antiproliferative and anticancer drug for neuroblastoma

Prajit Pillai, Shraddha Desai, David Ostrov, Hla Win and Mildred Acevedo-Duncan
Prajit Pillai
Univ. of South Florida, Tampa, FL, University of Florida, Gainesville, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shraddha Desai
Univ. of South Florida, Tampa, FL, University of Florida, Gainesville, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Ostrov
Univ. of South Florida, Tampa, FL, University of Florida, Gainesville, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hla Win
Univ. of South Florida, Tampa, FL, University of Florida, Gainesville, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mildred Acevedo-Duncan
Univ. of South Florida, Tampa, FL, University of Florida, Gainesville, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2008
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

Abstract

2387

Neuroblastomas are highly lethal tumors and 85% of cerebral neuroblastoma occurs in children and 15% in adults. Neuroblastoma is the fourth most common type of cancer in children. According to the American Cancer Society, there are approximately 650 new cases of neuroblastoma each year in the United States. Despite significant educational efforts, improved diagnostic techniques, and rigorous therapies, neuroblastoma control remains static. To address this health issue, the objectives of this research was to investigate the use protein kinase C-iota (PKC-ι) inhibitors on the proliferation of neuroblastoma cells. Previous work has shown that inhibition of PKC-ι is a promising means by which to prevent and treat certain cancers. Here, we report the identification of a PKC-ι inhibitor (1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy) methyl]cyclopentyl]-,[1R-(1α, 2β, 3β, 4α)] (ICA-1) that targets a unique sequence (amino acid residues 469-475) in the catalytic domain of PKC-ι, inhibits PKC-ι activity and is effective in blocking the proliferation of BE(2)C neuroblastoma cells. Our data support significant proof of concept that ICA-1 inhibits the proliferation of neuroblastoma cells and may be a novel chemotherapeutic for the treatment of patients with neuroblastoma.

Footnotes

  • 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 68 (9 Supplement)
May 2008
Volume 68, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
ICA-1: A novel antiproliferative and anticancer drug for neuroblastoma
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
ICA-1: A novel antiproliferative and anticancer drug for neuroblastoma
Prajit Pillai, Shraddha Desai, David Ostrov, Hla Win and Mildred Acevedo-Duncan
Cancer Res May 1 2008 (68) (9 Supplement) 2387;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
ICA-1: A novel antiproliferative and anticancer drug for neuroblastoma
Prajit Pillai, Shraddha Desai, David Ostrov, Hla Win and Mildred Acevedo-Duncan
Cancer Res May 1 2008 (68) (9 Supplement) 2387;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Novel Biological Therapy Agents: Poster Presentations - Proffered Abstracts

  • The BH3 mimetic Obatoclax (GX015-070) synergistically enhances TRAIL-mediated apoptosis by activating Bak and Bax in human pancreatic cancer cells
  • Preclinical in vitro and in vivo evaluation of the cyclin dependent kinase 2 inhibitor NU6102 and a water pro-drug NU6301
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement